Humanigen Announces Participation and Presentation at Multiple Conferences in September

BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that management will present and participate at multiple virtual investor conferences in September 2021. Details of the conferences are as follows:

Baird Global Healthcare Conference

Cameron Durrant, Chairman & CEO, will provide a corporate update at 5:30pm EDT on September 14, 2021. Access is limited, by the host of the conference, on an invitation only basis. Please contact your Baird representative for information on how to access the meeting.

H.C. Wainwright 23rd Annual Global Investment Conference

Cameron Durrant, Chairman & CEO participated in a panel to discuss “Best Practices Planning for the Next Pandemic”, which was pre-recorded and will be available starting at 12pm EDT on September 15, 2021.

Webcast: https://journey.ct.events/view/df4da74c-0a2c-499c-a5be-13f994a0d28f

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Presentation date: September 22, 2021

Presentation time: 2:05 ET

Webcast: Webcast link: https://wsw.com/webcast/oppenheimer16/hgen/2752454
The webcast will be archived for 90 days under the Investor Relations section of the company’s website at www.humanigen.com.

Cantor Global Healthcare 2021

Presentation date: September 27, 2021

Presentation time: 4:40 ET

Webcast link: https://wsw.com/webcast/cantor12/hgen/2064020
The webcast will be archived for 90 days under the Investor Relations section of the company’s website at www.humanigen.com.

About Humanigen

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen has submitted lenzilumab to Medicines and Health Regulatory Agency in the United Kingdom for a rolling review towards potential Marketing Authorization. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and, CD19-targeted CAR-T cell therapies, and exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements, including, without limitation, statements regarding our plans relating to lenzilumab.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the “Risk Factors” sections of our latest annual and quarterly reports and other filings with the SEC.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this presentation to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

Contacts

Humanigen Investor Relations
Ken Trbovich

Humanigen

[email protected]
650-410-3206